Jenburkt Pharma Reports Solid Q2 Growth Across Key Financial Metrics
Jenburkt Pharmaceuticals Limited announced improved Q2 financial results. Net profit increased by 5.83% to ₹101.6 crore, while revenue grew 10.56% to ₹455.5 crore. EBITDA rose 14.91% to ₹131.0 crore, with EBITDA margin expanding by 104 basis points to 28.76%. The company demonstrated growth across key financial metrics, indicating strong performance in the pharmaceutical sector.
*this image is generated using AI for illustrative purposes only.
Jenburkt Pharmaceuticals Limited, a prominent player in the Indian pharmaceutical sector, has announced its financial results for the second quarter, showcasing improvements across various financial parameters.
Financial Performance Highlights
The company has reported a notable increase in its key financial metrics for Q2:
| Metric | Q2 Current Year | Q2 Previous Year | YoY Change |
|---|---|---|---|
| Net Profit | ₹101.6 crore | ₹96.0 crore | +5.83% |
| Revenue | ₹455.5 crore | ₹412.0 crore | +10.56% |
| EBITDA | ₹131.0 crore | ₹114.0 crore | +14.91% |
| EBITDA Margin | 28.76% | 27.72% | +104 bps |
Profitability and Revenue Growth
Jenburkt Pharma's net profit for the quarter stood at ₹101.6 crore, marking a 5.83% increase from ₹96.0 crore in the same period last year. This growth in profitability comes alongside a substantial 10.56% year-over-year increase in revenue, which reached ₹455.5 crore compared to ₹412.0 crore in the previous year's corresponding quarter.
Improved Operational Performance
The company's operational performance showed significant improvement, with EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) rising to ₹131.0 crore from ₹114.0 crore in the year-ago period, representing a robust 14.91% increase.
Enhanced Profitability Margins
Notably, Jenburkt Pharma's EBITDA margin expanded by 104 basis points, reaching 28.76% compared to 27.72% in the same quarter of the previous year. This improvement in margin suggests enhanced operational efficiency and potentially better cost management by the company.
The positive financial results across revenue, profitability, and operational efficiency metrics indicate that Jenburkt Pharma has maintained a strong growth trajectory in the competitive pharmaceutical landscape.
17
